|
[1] YANG SZ,FENG XB,DONG JH. Surgical treatment of liver cancer guided by the concept of precision surgery[J]. J Pre Med,2018,33(3):189-192,196.(in Chinese)杨世忠，冯晓彬，董家鸿．精准外科理念指导下的肝癌外科治疗[J]．精准医学杂志，2018,33(3):189-192,196.
|
|
[2] CHEN Z,WANG J. Consideration in the diagnosis and treatment of hepatic cancer based onevidence-based guidelines and precision medicine[J]. Lingnan Mod Clin Surg,2018,18(6):615-617.(in Chinese)陈政，王捷．基于循证指南和精准医学时代背景下肝癌诊疗的思考与总结[J]．岭南现代临床外科，2018,18(6):615-617.
|
|
[3] LU SC,GU WQ. Essentials of precision medicine in practice of surgical oncology for hepatobiliary tumors[J]. Chin J Hepatobiliary Surg,2019,25(1):1-4.(in Chinese)卢实春，顾万清．肝胆肿瘤外科治疗精准医学概要[J]．中华肝胆外科杂志，2019,25(1):1-4.
|
|
[4] SCHULZE K,NAULT JC,VILLANUEVA A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing[J]. J Hepatol,2016,65(5):1031-1042.
|
|
[5] FORNER A,REIG M,BRUIX J. Hepatocellular carcinoma[J].Lancet,2018,391(10127):1301-1314.
|
|
[6] GAO Q,ZHU H,DONG L,et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma[J]. Cell,2019,179(5):1240.
|
|
[7] European Association for the Study of the Liver. EASL clinical practice guidelines:Management of hepatocellular carcinoma[J]. J Hepatol,2018,69(1):182-236.
|
|
[8] HEIMBACH JK,KULIK LM,FINN RS,et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology,2018,67(1):358-380.
|
|
[9] LLOVET JM,RICCI S,MAZZAFERRO V,et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med,2008,359:378-390.
|
|
[10] SCHULZE K,IMBEAUD S,LETOUZE,et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets[J]. Nat Genet,2015,47(5):505-511.
|
|
[11] GYAWALI B,PRASAD V. Health policy:Me-too drugs with limited benefits-the tale of regorafenib for HCC[J]. Nat Rev Clin Oncol,2017,14(11):653-654.
|
|
[12] SAWEY ET,CHANRION M,CAI C,et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening[J]. Cancer Cell,2011,19(3):347-358.
|
|
[13] VILGRAIN V,PEREIRA H,ASSENAT E,et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma(SARAH):An open-label randomised controlled phase 3 trial[J]. Lancet Oncol,2017,18(12):1624-1636.
|
|
[14] CHENG AL,KANG YK,CHEN Z,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:A phase III randomised,doubleblind,placebo-controlled trial[J]. Lancet Oncol,2009,10(1):25-34.
|
|
[15] BRUIX J,RAOUL JL,SHERMAN M,et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma:Subanalyses of a phase III trial[J]. J Hepatol,2012,57(4):821-829.
|
|
[16] MARRERO JA,KUDO M,VENOOK AP,et al. Observational registry of sorafenib use in clinical practice across ChildPugh subgroups:The GIDEON study[J]. J Hepatol,2016,65(6):1140-1147.
|
|
[17] FINN RS,MERLE P,GRANITO A,et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC:Additional analyses from the phase III RESORCE trial[J]. J Hepatol,2018,69(2):353-358.
|
|
[18] KUDO M,FINN RS,QIN S,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:A randomised phase 3 non-inferiority trial[J]. Lancet,2018,391(10126):1163-1173.
|
|
[19] CAINAP C,QIN S,HUANG WT,et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma:Results of a randomized phase III trial[J]. J Clin Oncol,2015,33(2):172-179.
|
|
[20] CHENG AL,KANG YK,LIN DY,et al. Sunitinib versus sorafenib in advanced hepatocellular cancer:Results of a randomized phase III trial[J]. J Clin Oncol,2013,31(32):4067-4075.
|
|
[21] BRUIX J,QIN S,MERLE P,et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE):A randomised,double-blind,placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064):56-66.
|
|
[22] KELLEY RK,VERSLYPE C,COHN AL,et al. Cabozantinib in hepatocellular carcinoma:Results of a phase 2 placebo-controlled randomized discontinuation study[J]. Ann Oncol,2017,28(3):528-534.
|
|
[23] ABOU-ALFA GK,MEYER T,CHENG AL,et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma[J]. N Engl J Med,2018,379(1):54-63.
|
|
[24] HEINRICH S,CASTVEN D,GALLE PR,et al. Translational considerations to improve response and overcome therapy resistance in immunotherapy for hepatocellular carcinoma[J].Cancers(Basel),2020,12(9):e2495.
|
|
[25] SANGRO B,GOMEZ-MARTIN C,de la MATA M,et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C[J]. J Hepatol,2013,59(1):81-88.
|
|
[26] ZHU AX,FINN RS,EDELINE J,et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224):A non-randomised,open-label phase 2 trial[J]. Lancet Oncol,2018,19(7):940-952.
|
|
[27] EL-KHOUEIRY AB,SANGRO B,YAU T,et al. Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate040):An open-label,non-comparative,phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088):2492-2502.
|
|
[28] FINN RS,RYOO BY,MERLE P,et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240:A randomized,double-blind,phase III trial[J]. J Clin Oncol,2020,38(3):193-202.
|
|
[29] REBOUISSOU S,LA BELLA T,REKIK S,et al. Proliferation markers are associated with MET expression in hepatocellular carcinoma and predict tivantinib sensitivity in vitro[J]. Clin Cancer Res,2017,23(15):4364-4375.
|
|
[30] HU Z,OTT PA,WU CJ. Towards personalized,tumour-specific,therapeutic vaccines for cancer[J]. Nat Rev Immunol,2018,18(3):168-182.
|
|
[31] NEELAPU SS,LOCKE FL,GO WY. CAR T-cell therapy in large B-cell lymphoma[J]. N Engl J Med,2018,378(11):1065.
|
|
[32] NEELAPU SS,TUMMALA S,KEBRIAEI P,et al. Chimeric antigen receptor T-cell therapy-assessment and management of toxicities[J]. Nat Rev Clin Oncol,2018,15(1):47-62.
|
|
[33] PARK R,ESHRAT F,AL-JUMAYLI M,et al. Immuno-oncotherapeutic approaches in advanced hepatocellular carcinoma[J]. Vaccines(Basel),2020,8(3):e447.
|
|
[34] PENG L,BIAN XW,LI DK,et al. Large-scale RNA-Seq transcriptome analysis of 4043 cancers and 548 normal tissue controls across 12 TCGA cancer types[J]. Sci Rep,2015,5:13413.
|
|
[35] FINN RS,QIN S,IKEDA M,et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med,2020,382(20):1894-1905.
|
|
[36] FINN RS,IKEDA M,ZHU AX,et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol,2020,38(26):2960-2970.
|
|
[37] KELLEY RK,W OLIVER J,HAZRA S,et al. Cabozantinib in combination with atezolizumab versus sorafenib in treatmentnaive advanced hepatocellular carcinoma:COSMIC-312Phase III study design[J]. Future Oncol,2020,16(21):1525-1536.
|
|
[38] GUARDASCIONE M,TOFFOLI G. Immune checkpoint inhibitors as monotherapy or within a combinatorial strategy in advanced hepatocellular carcinoma[J]. Int J Mol Sci,2020,21(17):e6302.
|
|
[39] FENG GS,HANLEY KL,LIANG Y,et al. Improving the efficacy of liver cancer immunotherapy:The power of combined preclinical and clinical studies[J]. Hepatology,2020.[Online ahead of print]
|
|
[40] ZHU XD,LI KS,SUN HC. Adjuvant therapies after curative treatments for hepatocellular carcincma:Current status and prospects[J]. Genes Dis,2020,7(3):359-369.
|
|
[41] CANALE M,ULIVI P,FOSCHI FG,et al. Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma[J]. Crit Rev Oncol Hematol,2018,129:44-53.
|
|
[42] ZHU HB,ZENG PH,GAO WH,et al. Discussion on the treatment of hepatocarcinoma with the multi-disciplinary integrated treatment team model combining traditional Chinese medicine and western medicine[J]. Guid J Tradit Chin Med Pharmacol,2019,25(22):21-24,31.(in Chinese)朱洪兵，曾普华，郜文辉，等．中西医联合MDT模式在肝癌治疗中的探讨[J]．中医药导报，2019,25(22):21-24,31.
|
|
[43] CHUMA M,UOJIMA H,NUMATA K,et al. Early changes in circulating FGF19 and Ang-2 levels as possible predictive biomarkers of clinical response to lenvatinib therapy in hepatocellular carcinoma[J]. Cancers(Basel),2020,12(2):293.
|
|
[44] LEE JJX,CHAN JJ,CHOO SP. Clinical development of cMET inhibition in hepatocellular carcinoma[J]. Diseases,2015,3(4):306-324.
|
|
[45] RIMASSA L,ABBADESSA G,PERSONENI N,et al. Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib[J]. Oncotarget,2016,7(45):72622-72633.
|
|
[46] JIANG Y,SUN A,ZHAO Y,et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma[J]. Nature,2019,567(7747):257-261.
|
DownLoad: